Half-Year 2022 Financial and Clinical Trials Update slide image

Half-Year 2022 Financial and Clinical Trials Update

Key launches 2022 Area Pathology Lab Product BenchMark ULTRA PLUS DP600 Core Lab Instruments Molecular Lab POC cobasⓇ pure integrated solutions cobasⓇ 5800 Digital LightCycler cobasⓇ pulse HER2 Low Breast Pathology Lab PRAME HPV Self Sampling cobasⓇ HCV Duo Tests Core Lab Elecsys pTau/AB42 ratio Gen2 (CSF) cobasⓇ SARS-CoV-2 DUO Molecular Lab cobas® 5800 Menu Expansion Chronic Kidney Disease InSight Cervical Cancer Screening Lab Insights Digital Solutions cobasⓇ infinity edge suite Diabetes Care Lab Insights Platform Payer Dashboard mySugar Pump V2.0 Description Automated immunohistochemistry/in situ hybridization (ISH) advanced staining platform with enhanced software capabilities, workflow and testing efficiency High capacity pathology slide scanner for high volume digitization applications Serum work area analyzer for low-to-medium sized labs Real-time PCR molecular testing for low volume labs Novel digital PCR platform for lab developed tests (LDTs) and in-vitro diagnostics labs Handheld device combining professional Glucose Meter and a digital platform to host Roche owned and 3rd party digital clinical decision support applications Assay for diagnosis of HER2 low expression breast cancer First immunohistochemistry assay for differential diagnosis of benign from malignant melanocytic lesions in skin cancer Self sample collection device for patients at home to collect sample for cervical cancer testing Antigen/antibody combined assay for faster diagnosis of hepatitis C Detect amyloid disease and enable a broader availability of testing for patients suspected of Alzheimer's Disease Automated RT-PCR assay for use on the cobas® 6800/8800 systems Assays to test for SARS-CoV-2, chlamydia trachomatis (CT)/neisseria gonorrhoeae (NG) and cytomegalovirus (CMV) Digital solution (mobile app and dashboard) providing insights for chronic kidney disease patient management Digital solution (mobile app and workflow) improving the management of screening programs for cervical cancer Portfolio of digital products to support decentralization of testing and data, to launch commercially with an open ecosystem Market Status US & CE WW US US WW US US US & CE CE CE US US² & OUS1 US & CE CE CE 씽씽 CE Data integration platform for laboratory customers across disciplines Population-level insights via dashboard for HCPs, Admins and Payers Extended functionalities (e.g. temporary basal rate import from a connected insulin pump), expanded smartphone compatibility CE OUS3 OUS3 CE: European Conformity, US: FDA approval, WW: Worldwide including CE, US and China, OUS: Outside the US; PCR: Polymerase Chain Reaction; RT: Real Time; 1 Research Use Only; 2 EUA: Emergency Use Authorization; 3 Only selected countries Roche 48
View entire presentation